(Q28212180)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

review article

1 reference

title

Cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

Gerd Döring

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

language of work or name

English

0 references

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

361

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

9358

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

681-689

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Identification of the cystic fibrosis gene: chromosome walking and jumping

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Cystic fibrosis: molecular biology and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Correlation between genotype and phenotype in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

The origin of the major cystic fibrosis mutation (delta F508) in European populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Evidence for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary cell cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Chloride channel and chloride conductance regulator domains of CFTR, the cystic fibrosis transmembrane conductance regulator

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl- channel function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

The neglected ion: HCO3-

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Inflammation and infection in naive human cystic fibrosis airway grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Lower airway inflammation in infants and young children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Noninvasive in vivo fluorescence measurement of airway-surface liquid depth, salt concentration, and pH.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

The cystic fibrosis gene and resting energy expenditure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Male fertility in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Water and electrolytes in cervical mucus from patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

The diagnosis of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Making the diagnosis of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Time to think again: cystic fibrosis is not an "all or none" disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Stool trypsin and chymotrypsin. Value in the diagnosis of pancreatic insufficiency in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Faecal elastase 1: a marker of exocrine pancreatic insufficiency in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

PARANASAL SINUSES IN CYSTIC FIBROSIS. INCIDENCE OF ROENTGEN ABNORMALITIES

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Nutrition and survival in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Gene therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

The changing epidemiology of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Long-term tobramycin aerosol therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Long-term azithromycin may improve lung function in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Effect of high-dose ibuprofen in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Aerosol α1 -antitrypsin treatment for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Survival effect of lung transplantation among patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Lung transplantation and life extension in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Prediction of Mortality in Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Living donor lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Nutrition in patients with cystic fibrosis: a European Consensus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

Transplantation for cystic fibrosis: outcome following early liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

International comparison of median age at death from cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912567-6

7 January 2021

10.1016/S0140-6736(03)12567-6

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12606185%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017